Members log in

Remember me

Do not refresh my screen on timeout

close

News

ABN Clinical Research Fellowship deadline: Sunday 18 November 2018.

Read More

Events

ABN Annual Meeting 2019: 21 - 23 May 2019 - The EICC, Edinburgh

Read More

Evan Edmond

Biomarkers and Modulation of Cortical Hyperexcitability in ALS.

Amyotrophic lateral sclerosis (ALS) is a progressive, fatal condition involving degeneration of the motor system – parts of the brain, spinal cord and nerves that control muscles. At least 5000 people in the UK are living with ALS, and many more bear the physical and emotional burden of their care. The average time from first symptoms to death is 3 years. Around 10% of all cases of ALS are caused by a specific abnormality in the affected person’s genetic code.

New medications, including revolutionary genetic treatments for ALS, are being actively developed. To show that they are effective in slowing disease, sensitive markers of disease activity (biomarkers) are urgently needed. The motor output of the brain is over-active in ALS, referred to as cortical hyperexcitability. I will use advanced non-invasive brain scanning as a source of biomarkers for cortical hyperexcitability. I will also attempt to reduce the brain’s motor excitability in ALS patients using a technique called non-invasive brain stimulation.

I will study a group of affected people carrying the abnormal genetic code, and a group with the same gene who have not yet developed the disease. By comparing the biomarkers in both affected individuals and symptom-free genetic carriers, I hope to identify the earliest changes. Future treatments might then target the disease before a person is aware of weakness. Sensitive biomarkers for those already affected by ALS will help to make clinical trials faster and cheaper, accelerating the prospects for better treatments.

 

News

ABN Clinical Research Fellowship deadline: Sunday 18 November 2018.

Read More

Events

ABN Annual Meeting 2019: 21 - 23 May 2019 - The EICC, Edinburgh

Read More